DOCSLIB.ORG

Dietpower Sample

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dietpower Sample dnaPwer POWER OVER YOUR HEALTH YOUR dietPwer RESULTS PPerersonal DNA Rsonal Report feport for:or: Dale Bosa Private and Con!den5al February 14 2019 #41001801514600-72 dietPwer Your Personal DNA Results CongrCongraatulatula5ons5ons on making the decision tto to takake Pe Poowwer oer ovver yer your Health!our Health! Your personalized DNA results contain inforMa5on unique to your body, giving you the power to make inforMed decisions about your health. WHY DNA IS IMPORTANT RELIABLE RESULTS DNA is our personal biological roadmap. It guides the development dnaPower uses a state of the art Agena and func5oning of our bodies. DNA sequences, known as genes, MassArray genotyping pla4orM to provide contain gene5c markers that di er among people. dnaPower’s greater than 99.7% accuracy in the genes gene5c tes5ng zeros in on speci!c genes and gene5c markers that and SNPs (Single Nucleo5de have been scien5!cally proven to impact health, nutri5on, !tness, PolyMorphisms) that we test. We test and disease and that may vary between people. gene5c sites that iden5fy the most comMon DNA markers scien5!cally studied HOW GENETIC VARIATIONS CAN IMPACT YOUR HEALTH and proven to be associated with certain Hereditary and environmental factors can cause gene5c varia5ons condi5ons. We report on genes that have a or muta5ons in your DNA. Some muta5ons have minimal e ects, high incidence rela5onship. It is important while others may alter a gene in such a way that its func5on is to note that DNA research is constantly changed or lost. When this occurs, there is a risk that your gene evolving. There may be varia5ons related may not func5on at an op5mum level. to a condi5on that are yet to be discovered and may in future improve on the accuracy HOW YOUR DNA RESULTS CAN HELP YOU and thoroughness of the results. Your dnaPower results provide a snapshot of selected gene5c varia5ons that have been proven through scien5!c studies to MAXIMIZING YOUR RESULTS impact your health. By knowing your gene5c varia5ons, you can Knowledge is power. We encourage you to learn where you may be predisposed to good or poor health use your dnaPower results to understand related traits. By understanding this inforMa5on, you can take poten5al impacts to your health and to proac5ve steps to enhance your wellbeing. The good news is that take posi5ve ac5on. We recomMend through healthy diet, nutri5on and exercise, you can change or consul5ng a quali!ed health prac55oner to improve how your DNA func5ons. gain further insight and advice for a program speci!c to you. dnaPwer | 2 www.dnaPower.com dietPwer How To Read Your Report YOUR SUMMARY A snapshot of each area tested and your gene5c composi5on results. PAGE 4 YOUR ACTION PLAN Key suggested ac5ons based on areas with higher varia5ons. PAGE 7 YOUR DETAILED TEST AREA DESCRIPTIONS Detailed inforMa5on on each test area along with further 5ps to take power over your health. PAGE 10 YOUR GENETIC PROFILE Your personal genotype results for each gene tested. PAGE 60 READING YOUR GENETIC COMPOSITION GRAPH 87% 13% NORMAL VARIATION Your personal results are represented in a gene5c composi5on graph. GrGreen is Goodeen Good. Indicates the percentage of gene(s) or SNPs tested that are norMal. With good health decisions, your gene(s) should func5on properly. RRed is Ped Pooroor. Indicates there are varia5ons in the gene(s) or SNPs that have poten5al to impact your health. This is a possible area of risk. Take proac5ve ac5on to look a%er your health. In yIn your rour reporteport, focus on areas that are 50% red or more as this is where you are more likely to experience issues over 5me. dnaPwer | 3 www.dnaPower.com dietPwer YOUR dietPwer SUMMARY Your personal report covers your gene5c composi5on for results related to diet, nutri5on, suppleMents and weight Management. The results give you an indica5on of your predisposi5on to the health factors tested. Your gene5cs are your blueprint. You can enhance and improve your health outcomes through diet, !tness and environment. AREA TESTED TELLS YOU (Risk Potential) YOUR GENETIC COMPOSITION RESULTS PAGE DIET MANAGEMENT Carbohydrate Your ability to process 11 carbohydrates in your diet 80% 20% Insulin Your ability to regulate blood 12 sugar through insulin 75% 25% HDL Cholesterol How well you regulate HDL 13 cholesterol 80% 20% LDL Cholesterol How well you regulate LDL 14 cholesterol 90% 10% Dietary Unsaturated Fat Your ability to metabolize 15 unsaturated fats in your diet 100% Dietary Saturated Fat How well you metabolize 16 saturated fats in your diet 17% 83% Stored Body Fat How well your body burns stored 17 fats 87% 13% Protein Need Your need for a norMal amount of 18 dietary protein 50% 50% Protein Weight Response Your weight response to a high 19 protein diet 100% WEIGHT RESPONSE Body Mass Index Your ability to regulate your body 21 Mass index 40% 60% Normal Genes Variations dnaPwer | 4 www.dnaPower.com dietPwer YOUR dietPwer SUMMARY Your personal report covers your gene5c composi5on for results related to diet, nutri5on, suppleMents and weight Management. The results give you an indica5on of your predisposi5on to the health factors tested. Your gene5cs are your blueprint. You can enhance and improve your health outcomes through diet, !tness and environment. AREA TESTED TELLS YOU (Risk Potential) YOUR GENETIC COMPOSITION RESULTS PAGE F OOD TOLERANCES Alcohol How well your body metabolizes 23 alcohol 100% Ca eine How well your body processes 24 ca eine 100% Gluten Your norMal risk for gluten 25 sensi5vity 67% 33% Lactose How well your body digests 26 lactose from dairy products 100% How well you metabolize salt Salt 50% 50% 27 Sugar Craving Your ability to resist sugar cravings 28 and sweet foods 75% 25% F OOD TASTE AND PREFERENCE Carbohydrate Preference Your preference to consume a 30 norMal amount of carbohydrates 100% Fat Preference Your preference to consume a 31 norMal amount of fats 75% 25% Protein Preference Your preference to consume a 32 norMal amount of protein 100% Bi6er Taste Your ability to taste bi6er #avours 33 and foods 100% Salt Taste Your ability to taste salt and salty 34 foods 67% 33% Sweet Taste Your ability to taste sweet #avours 35 and foods 100% Smoking Behaviour Your ability to respond norMally to 36 nico5ne 50% 50% Normal Genes Variations dnaPwer | 5 www.dnaPower.com dietPwer YOUR dietPwer SUMMARY Your personal report covers your gene5c composi5on for results related to diet, nutri5on, suppleMents and weight Management. The results give you an indica5on of your predisposi5on to the health factors tested. Your gene5cs are your blueprint. You can enhance and improve your health outcomes through diet, !tness and environment. AREA TESTED TELLS YOU (Risk Potential) YOUR GENETIC COMPOSITION RESULTS PAGE VITAMINS & SUPPLEMENTS Vitamin A How well you convert vitamin A 38 for healthy growth and imMune 50% 50% response Vitamin B6 How well you process vitamin B6 39 for macronutrient metabolism 50% 50% Vitamin B9 (Folate) How well you process folate for 40 cell growth and healthy red blood 62% 38% cells Vitamin B12 How well you process vitamin B12 41 for healthy nerve and blood cells 100% Vitamin C How well you process vitamin C 42 for growth and development 67% 33% Vitamin D How well you process vitamin D to 43 support calcium absorp5on and 69% 31% cell growth Vitamin E How well you convert vitamin E 44 for an5oxidant and an5-aging 67% 33% bene!ts Calcium How well your body absorbs 45 calcium for bones, teeth and 67% 33% Muscles Iodine How well your body transports 46 iodine to support thyroid func5on 100% Iron De!ciency How well your body absorbs iron 47 for red blood cells to carry oxygen 75% 25% Iron Overload How well your body regulates iron 48 for red blood cells to carry oxygen 75% 25% Omega 3 Your need for bene!cial omega 3 49 fa6y acids for metabolism, brain 80% 20% health and reducing disease Omega 6 Your ability to process omega 6 in 50 your diet 100% Normal Genes Variations dnaPwer | 6 www.dnaPower.com dietPwer YOUR dietPwer ACTION PLAN Your personal DNA results provide valuable insights into your body based on your unique gene5c code. This is a suggested dietPower Ac5on Plan based on your personal DNA results. We have provided you with Ac5on Tips that may help support your DNA and health. The areas below are where you have higher gene5c varia5ons (>50% red in the Gene5c Composi5on graphs). This increases your risk poten5al in that area over 5me. By taking ac5on to support your health in these areas and managing lifestyle factors such as diet, exercise, sleep, stress and environmental factors, you increase the opportunity for your genes to func5on op5mally. AREA TESTED ACTION TIPS PAGE DIET MANAGEMENT Avoid ea5ng a diet high in saturated fats and focus instead on healthier 16 Dietary Saturated Fat unsaturated fats such as #axseed oil, heMp seeds, leafy greens, walnuts and chia seeds. Reduce dairy and fa6y meats, and par5cularly avoid processed and prepared foods as they have a higher likelihood of contribu5ng to weight gain. Focus on ea5ng a balanced healthy diet and exercising regularly. Consider ea5ng smaller, more frequent amounts of proteins which are 18 Protein Need easier for your body to digest including plant-based proteins such as beans, len5ls, peas and quinoa as well as !sh, co6age cheese, eggs, protein powders, nuts, seeds, and sea vegetables. F OOD TOLERANCES Consider reducing or avoiding milk and dairy products and using dairy 26 Lactose alterna5ves made from coconut, cashew, almonds, rice or soy. High varia5ons can contribute to weight gain and in#amMa5on over 5me.
Load more

Recommended publications
  • Association Between Hereditary Hemochromatosis and Hepatocellular Carcinoma: a Comprehensive Review
    Jayachandran et al. Hepatoma Res 2020;6:8 Hepatoma Research DOI: 10.20517/2394-5079.2019.35 Review Open Access Association between hereditary hemochromatosis and hepatocellular carcinoma: a comprehensive review Aparna Jayachandran1,2, Ritu Shrestha1,2, Kim R. Bridle1,2, Darrell H. G. Crawford1,2 1The University of Queensland, Faculty of Medicine, Brisbane, QLD 4006, Australia. 2Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia. Correspondence to: Prof. Darrell H. G. Crawford, Gallipoli Medical Research Institute, The University of Queensland, Faculty of Medicine, Lower Lobby Level, Administration Building, Greenslopes Private Hospital, Greenslopes, QLD 4120, Australia. E-mail: [email protected] How to cite this article: Jayachandran A, Shrestha R, Bridle KR, Crawford DHG. Association between hereditary hemochromatosis and HCC: a comprehensive review. Hepatoma Res 2020;6:8. http://dx.doi.org/10.20517/2394-5079.2019.35 Received: 15 Nov 2019 First Decision: 10 Dec 2019 Revised: 4 Feb 2020 Accepted: 18 Feb 2020 Published: 6 Mar 2020 Science Editor: Guang-Wen Cao Copy Editor: Jing-Wen Zhang Production Editor: Tian Zhang Abstract Hepatocellular carcinoma (HCC) is a significant global health problem with high morbidity and mortality. Its incidence is increasing exponentially worldwide with a close overlap between annual incidence and death rates. Even though significant advances have been made in HCC treatment, fewer than 20% of patients with HCC are suitable for potentially curative treatment. Hereditary hemochromatosis (HH) is an important genetic risk factor for HCC. HH is an autosomal recessive disorder of iron metabolism, characterised by elevated iron deposition in most organs including the liver, leading to progressive organ dysfunction.
    [Show full text]
  • Nr EC Aandoening Orphacode Patiëntenorganisatie Vragenlijst
    Nr EC Aandoening Orphacode Patiëntenorganisatie Vragenlijst P PNR ingediend? G-24-12 ABeta amyloidosis, Dutch type ORPHA:100006 Vereniging HCHWA-D Nee P 14 G-8-7 Tubular duplication of the esophagus ORPHA:100048 Vereniging voor Ouderen en Kinderen met Slokdarmafsluiting (VOKS) Ja P 124 G-17-10 Neurogenic thoracic outlet syndrome ORPHA:100073 RSI-vereniging Nee P 305 G-11-43 Laryngeal neuroendocrine tumor ORPHA:100083 St NET-Groep Ja P 62 G-11-43 Middle ear neuroendocrine tumor ORPHA:100084 St NET-Groep Ja P 62 G-11-1 Thyroid tumor ORPHA:100087 Schildklier Organisatie NL (SON) Ja P 60 G-11-13 Thyroid tumor ORPHA:100087 Schildklier Organisatie NL (SON) Ja P 60 G-11-35 Thyroid Tumor ORPHA:100087 Schildklier Organisatie NL (SON) Ja P 60 G-11-13 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-11-35 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-3-11 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-3-17 Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) Ja P 60 G-3-13 Adrenal/paraganglial tumor ORPHA:100091 Nlse Vereniging voor patiënten met Paragangliomen (NVPG) Ja P 29 G-3-13 Adrenal/paraganglial tumor ORPHA:100091 Bijniervereniging (NVACP) Nee P 64 G-3-2 Adrenal/paraganglial tumor ORPHA:100091 Nlse Vereniging voor Patiënten met Paragangliomen (NVPG) Ja P 29 G-3-2 Adrenal/paraganglial tumor ORPHA:100091 Bijniervereniging (NVACP) Nee P 64 G-11-29 Gastroenteropancreatic neuroendocrine neoplasm ORPHA:100092 St NET-Groep Ja P 62 G-11-27 Thymic tumor ORPHA:100100
    [Show full text]
  • Do Pregnancies Reduce Iron Overload In
    Scotet et al. BMC Pregnancy and Childbirth (2018) 18:53 https://doi.org/10.1186/s12884-018-1684-6 RESEARCH ARTICLE Open Access Do pregnancies reduce iron overload in HFE hemochromatosis women? results from an observational prospective study Virginie Scotet1*†, Philippe Saliou1,2†, Marianne Uguen1, Carine L’Hostis1, Marie-Christine Merour3, Céline Triponey3, Brigitte Chanu3, Jean-Baptiste Nousbaum1,4, Gerald Le Gac1,5 and Claude Ferec1,3,5 Abstract Background: HFE hemochromatosis is an inborn error of iron metabolism linked to a defect in the regulation of hepcidin synthesis. This autosomal recessive disease typically manifests later in women than men. Although it is commonly stated that pregnancy is, with menses, one of the factors that offsets iron accumulation in women, no epidemiological study has yet supported this hypothesis. The aim of our study was to evaluate the influence of pregnancy on expression of the predominant HFE p.[Cys282Tyr];[Cys282Tyr] genotype. Methods: One hundred and forty p.Cys282Tyr homozygous women enrolled in a phlebotomy program between 2004 and 2011 at a blood centre in western Brittany (France) were included in the study. After checking whether the disease expression was delayed in women than in men in our study, the association between pregnancy and iron overload was assessed using multivariable regression analysis. Results: Our study confirms that women with HFE hemochromatosis were diagnosed later than men cared for during the same period (52.6 vs. 47.4 y., P < 0.001). Compared to no pregnancy, having at least one pregnancy was not associated with lower iron markers. In contrast, the amount of iron removed by phlebotomies appeared significantly higher in women who had at least one pregnancy (eβ = 1.50, P = 0.047).
    [Show full text]
  • Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome
    Cardiorenal Med 2016;6:83–98 DOI: 10.1159/000441283 © 2015 S. Karger AG, Basel Published online: November 6, 2015 1664–3828/15/0062–0083$39.50/0 www.karger.com/crm Review Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome a, c a, c, f d b Yoshitsugu Obi Taehee Kim Csaba P. Kovesdy Alpesh N. Amin a, c, e Kamyar Kalantar-Zadeh a b Division of Nephrology and Hypertension and Department of Medicine, University of c California Irvine, and Harold Simmons Center for Kidney Disease Research and d Epidemiology, Orange, Calif., Division of Nephrology, University of Tennessee Health e Sciences Center, Memphis, Tenn. , and Department of Medicine, VA Long Beach f Health Care System, Long Beach, Calif., USA; Department of Medicine, Inje University, Busan , South Korea Key Words Cardiorenal syndrome · Chronic kidney disease · Heart failure · Acute kidney injury · Dobutamine · Ultrafiltration Abstract Background: Cardiorenal syndrome (CRS) encompasses conditions in which cardiac and renal disorders co-exist and are pathophysiologically related. The newest classification of CRS into seven etiologically and clinically distinct types for direct patient management pur- poses includes hemodynamic, uremic, vascular, neurohumoral, anemia- and/or iron metab- olism-related, mineral metabolism-related and protein-energy wasting-related CRS. This classification also emphasizes the pathophysiologic pathways. The leading CRS category remains hemodynamic CRS, which is the most commonly encountered type in patient care settings and in which acute or chronic heart failure leads to renal impairment. Summary: This review focuses on selected therapeutic strategies for the clinical management of he- modynamic CRS. This is often characterized by an exceptionally high ratio of serum urea to creatinine concentrations.
    [Show full text]
  • Orphanet Aandoening Orphacode Patiëntenorganisatie P
    Cluster(s) Orphanet Aandoening Orphacode Patiëntenorganisatie P PNR -U UNR Rare genetic diseases ABeta amyloidosis, Dutch type ORPHA:100006 Vereniging HCHWA-D P 14 U 2003 Rare neurological diseases Rare respiratory diseases Tubular duplication of the esophagus ORPHA:100048 Vereniging voor Ouderen en Kinderen met Slokdarmafsluiting (VOKS) P 124 U 495 Rare surgical thoracic diseases Rare surgical thoracic diseases Neurogenic thoracic outlet syndrome ORPHA:100073 RSI-vereniging P 305 U 6 Rare neurological diseases Neurogenic thoracic outlet syndrome ORPHA:100073 Spierziekten NL P 43 U 1418 Rare neoplastic diseases Laryngeal neuroendocrine tumor ORPHA:100083 ST NET-Groep P 62 U 1199 Rare odontological diseases Rare bone diseases Rare otorhinolaryngological diseases Rare skin diseases Rare surgical maxillo-facial diseases Rare neoplastic diseases Middle ear neuroendocrine tumor ORPHA:100084 ST NET-Groep P 62 U 1200 Rare odontological diseases Rare bone diseases Rare otorhinolaryngological diseases Rare skin diseases Rare surgical maxillo-facial diseases Rare endocrine diseases Thyroid tumor ORPHA:100087 Schildklier Organisatie NL (SON) P 60 U 1214 Rare neoplastic diseases Rare endocrine diseases Thyroid tumor ORPHA:100087 Schildklier Organisatie NL (SON) P 60 U 1213 Rare endocrine diseases Thyroid Tumor ORPHA:100087 Schildklier Organisatie NL (SON) P 60 U 1215 Rare neoplastic diseases Rare endocrine diseases Thyroid carcinoma ORPHA:100088 Schildklier Organisatie NL (SON) P 60 U 1216 Rare endocrine diseases Thyroid carcinoma ORPHA:100088 Schildklier
    [Show full text]
  • WO 2014/121298 A2 7 August 2014 (07.08.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/121298 A2 7 August 2014 (07.08.2014) P O P C T (51) International Patent Classification: VULIC, Marin; c/o Seres Health, Inc., 161 First Street, A61K 39/02 (2006.01) Suite 1A, Cambridge, MA 02142 (US). (21) International Application Number: (74) Agents: HUBL, Susan, T. et al; Fenwick & West LLP, PCT/US2014/014738 Silicon Valley Center, 801 California Street, Mountain View, CA 94041 (US). (22) International Filing Date: 4 February 2014 (04.02.2014) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 61/760,584 4 February 2013 (04.02.2013) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/760,585 4 February 2013 (04.02.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/760,574 4 February 2013 (04.02.2013) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 61/760,606 4 February 2013 (04.02.2013) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 61/926,918 13 January 2014 (13.01.2014) us TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant: SERES HEALTH, INC.
    [Show full text]
  • Wjcc.V8.I23.5962 ISSN 2307-8960 (Online)
    World Journal of W J C C Clinical Cases Submit a Manuscript: https://www.f6publishing.com World J Clin Cases 2020 December 6; 8(23): 5962-5975 DOI: 10.12998/wjcc.v8.i23.5962 ISSN 2307-8960 (online) ORIGINAL ARTICLE Observational Study Genetic diagnosis history and osteoarticular phenotype of a non- transfusion secondary hemochromatosis Dan-Dan Ruan, Yu-Mian Gan, Tao Lu, Xiao Yang, Yao-Bin Zhu, Qing-Hua Yu, Li-Sheng Liao, Ning Lin, Xin Qian, Jie-Wei Luo, Fa-Qiang Tang ORCID number: Dan-Dan Ruan Dan-Dan Ruan, Yu-Mian Gan, Tao Lu, Qing-Hua Yu, Li-Sheng Liao, Ning Lin, Xin Qian, Jie-Wei Luo, 0000-0001-9611-2979; Yu-Mian Gan Fa-Qiang Tang, Shengli Clinical Medical College, Fujian Medical University, Fuzhou 350001, 0000-0003-3676-1242; Tao Lu 0000- Fujian Province, China 0002-6807-9152; Xiao Yang 0000- 0003-2091-7126; Yao-Bin Zhu 0000- Xiao Yang, Department of Management, Fujian Health College, Fuzhou 350101, Fujian 0003-2186-2286; Qing-Hua Yu 0000- Province, China 0002-3465-6417; Li-Sheng Liao 0000- 0001-7364-4366; Ning Lin 0000- Yao-Bin Zhu, Department of Traditional Chinese Medicine, The First Affiliated Hospital, Fujian 0003-4911-7309; Xin Qian 0000- Medical University, Fuzhou 350005, Fujian Province, China 0001-7239-7295; Jie-Wei Luo 0000- 0003-4271-4848; Fa-Qiang Tang Fa-Qiang Tang, Department of Orthopedics, Fujian Provincial Hospital, Fuzhou 350001, Fujian 0000-0002-0625-8470. Province, China Author contributions: Ruan DD, Corresponding author: Fa-Qiang Tang, MD, Chief Physician, Doctor, Shengli Clinical Medical Gan YM, Lu T, Yang X and Zhu YB College, Fujian Medical University, No.
    [Show full text]
  • Abnormal Serum Iron Markers in Chronic Hepatitis B Virus Infection May Be Because of Liver Injury Weilin Maoa, Ying Hub, Yufeng Loua, Yuemei Chena and Juanwen Zhanga
    130 Original article Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury WeiLin Maoa, Ying Hub, YuFeng Loua, YueMei Chena and JuanWen Zhanga Objective In patients with chronic hepatitis B virus (HBV) inversely related to both end-stage liver disease scores infection, it is not known whether altered serum iron and iron levels (all P < 0.01). markers are directly because of the infection or the Conclusion Serum iron markers tended to be aberrant in associated liver injury. We determined the serum iron status chronic HBV-infected patients with cirrhosis. The liver injury of patients with chronic HBV infection, and investigated associated with HBV infection, but not chronic HBV infection whether it is HBV infection or HBV-related liver injury that directly, is likely the main cause for iron metabolism likely causes abnormal serum iron markers in chronic HBV disorder. Eur J Gastroenterol Hepatol 27:130–136 © 2015 infection. Wolters Kluwer Health | Lippincott Williams & Wilkins. Materials and methods For a retrospective study, chronic European Journal of Gastroenterology & Hepatology 2015, 27:130–136 HBV-infected patients (80 patients with cirrhosis and 76 patients without cirrhosis) and 58 healthy controls were Keywords: ferritin, liver cirrhosis, liver injury, serum iron, transferrin enrolled. Serum alanine transaminase levels were Departments of aClinical Laboratory and bUltrasonography, the First Affiliated measured to ascertain liver damage. Indicators of iron Hospital, College of Medicine,
    [Show full text]
  • Topics Symposia
    Abstracts Topics Symposia Symposia S_1 Structural variation S 1 Structural variation S 2 Low risk cancer genes S1_01 S 3 Transgeneration effects and Molecular Mechanisms and Clinical Consequences of Genomic Disor- epigenetic programming ders. Implementation of array CGH in Genetic Diagnostics. The Baylor S 4 Ciliopathies Experience S 5 Systems biology Pawel Stankiewicz S 6 Molecular processes in meiosis Dept. of Molecular & Human Genetics, Baylor College of Medicine, Hous- ton, TX, USA Genomic disorders are a group of human genetic diseases caused by Selected Presentations DNA rearrangements, ranging in size from an average exon (~100 bp) to megabases and affecting dosage sensitive genes. Three major mo- lecular mechanisms: non-allelic homologous recombination (NAHR), Workshops non-homologous end joining (NHEJ), and the fork stalling and tem- W 1 Clinical genetics plate switching (FoSTeS)/microhomology-mediated breakage-induced W 2 Molecular basis of disease I repair (MMBIR) have been described as causative for the vast majority W 3 Cancer genetics of genomic disorders. Recurrent rearrangements are typically mediated W 4 Molecular basis of disease II by NAHR between low-copy repeats that are usually >10 kb in size with >97% DNA sequence identity. Nonrecurrent CNVs have been found to W 5 Imprinting be formed by NAHR between highly homologous repetitive elements W 6 Genomics technology / bioinformatics (e.g. Alu, LINE) and more often by NHEJ and FoSTeS/MMBIR stimu- W 7 Complex diseases lated, but not mediated, by genomic architectural features. Further- W 8 Cytogenetics / prenatal genetics more, simple repeating DNA sequences that have a potential of adopt- ing non-B DNA conformations (e.g.
    [Show full text]
  • U UNR Aandoening Orphacode Patiëntenorganisatie P 296
    P PNR -U UNR Aandoening Orphacode Patiëntenorganisatie P 296 U 21 Anterior cutaneous nerve entrapment syndrome ORPHA:51890 ACNES Foundation P 296 U 22 Anterior cutaneous nerve entrapment syndrome ORPHA:51890 ACNES Foundation P 1 U 1837 Rare ataxia ORPHA:102002 ADCA-Ataxie Vereniging P 1 U 1838 Rare ataxia ORPHA:102002 ADCA-Ataxie Vereniging P 1 U 1839 Autosomal recessive cerebellar ataxia ORPHA:1172 ADCA-Ataxie Vereniging P 1 U 1840 Epilepsy and/or ataxia with myoclonus as major feature ORPHA:306756 ADCA-Ataxie Vereniging P 1 U 1841 Autosomal dominant cerebellar ataxia ORPHA:99 ADCA-Ataxie Vereniging P 1 U 1842 Autosomal dominant cerebellar ataxia ORPHA:99 ADCA-Ataxie Vereniging P 1 U 1907 CLIPPERS ORPHA:284448 ADCA-Ataxie vereniging P 268 U 90 Amyotrophic lateral sclerosis ORPHA:803 ALS Patients Connected P 268 U 91 Amyotrophic lateral sclerosis ORPHA:803 ALS Patients Connected P 268 U 92 amyotrophic lateral sclerosis-parkinsonism-dementia complex ORPHA:90020 ALS Patients Connected P 2 U 1821 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:136 Alzheimer NL P 2 U 1822 Pantothenate kinase-associated neurodegeneration ORPHA:157850 Alzheimer NL P 2 U 1823 Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy ORPHA:199354 Alzheimer NL P 2 U 1827 neuronal intranuclear inclusion disease ORPHA:2289 Alzheimer NL P 2 U 1828 Frontotemporal dementia with motor neuron disease ORPHA:275872 Alzheimer NL P 2 U 1829 Frontotemporal dementia ORPHA:282 Alzheimer NL P 2 U 1830 Neurodegeneration
    [Show full text]
  • (12) STANDARD PATENT (11) Application No. AU 2010202722 B2 (19) AUSTRALIAN PATENT OFFICE
    (12) STANDARD PATENT (11) Application No. AU 2010202722 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof (51) International Patent Classification(s) C12Q 1/68 (2006.01) G01N 33/50 (2006.01) C07K 14/47 (2006.01) (21) Application No: 2010202722 (22) Date of Filing: 2010.06.29 (43) Publication Date: 2010.07.15 (43) Publication Journal Date: 2010.07.15 (44) Accepted Journal Date: 2012.12.20 (62) Divisional of: 2004231122 (71) Applicant(s) Xenon Pharmaceuticals, Inc. (72) Inventor(s) Ludwig, Erwin H.;Papanikolaou, George;MacDonald, Marcia L.E.;Samuels, Mark E.;Franchini, Patrick;Kamboj, Rajender K.;Goldberg, Yigal Paul (74) Agent / Attorney Spruson & Ferguson, L 35 St Martins Tower 31 Market St, SYDNEY, NSW, 2000 (56) Related Art WO 2000/073801 WO 2002/051438 GenBank Accession No: BAB26407 JUVENILE HEMOCHROMATOSIS GENE (HFE2A), EXPRESSION PRODUCTS 2010 AND USES THEREOF Jun Abstract 29 5 Polynucleotide and polypeptide sequences for HFE2A, as well as mutations associated with juvenile hemochromatosis, and methods of utilizing these for screening and identification of agents for the treatment of diseases of iron metabolism, including small organic compounds, are disclosed along with methods of treating and/or io ameliorating diseases of iron metabolism, especially in human patients are disclosed. 2010202722 Diagnostic compounds, kits and methods using HFE2A are also described. S&FRef: 739254D1 AUSTRALIA 2010 PATENTS ACT 1990 COMPLETE SPECIFICATION Jun 29 FOR A STANDARD PATENT 2010202722 Name and Address Xenon Pharmaceuticals, Inc., of 3650 Gilmore Way, of Applicant: Burnaby, British Columbia, V5G 4W8, Canada Actual Inventor(s): Erwin H.
    [Show full text]
  • Thi Na Utaliblat in Un Minune Talk
    THI NA UTALIBLATUS010064900B2 IN UN MINUNE TALK (12 ) United States Patent ( 10 ) Patent No. : US 10 , 064 ,900 B2 Von Maltzahn et al . ( 45 ) Date of Patent: * Sep . 4 , 2018 ( 54 ) METHODS OF POPULATING A (51 ) Int. CI. GASTROINTESTINAL TRACT A61K 35 / 741 (2015 . 01 ) A61K 9 / 00 ( 2006 .01 ) (71 ) Applicant: Seres Therapeutics, Inc. , Cambridge , (Continued ) MA (US ) (52 ) U . S . CI. CPC .. A61K 35 / 741 ( 2013 .01 ) ; A61K 9 /0053 ( 72 ) Inventors : Geoffrey Von Maltzahn , Boston , MA ( 2013. 01 ); A61K 9 /48 ( 2013 . 01 ) ; (US ) ; Matthew R . Henn , Somerville , (Continued ) MA (US ) ; David N . Cook , Brooklyn , (58 ) Field of Classification Search NY (US ) ; David Arthur Berry , None Brookline, MA (US ) ; Noubar B . See application file for complete search history . Afeyan , Lexington , MA (US ) ; Brian Goodman , Boston , MA (US ) ; ( 56 ) References Cited Mary - Jane Lombardo McKenzie , Arlington , MA (US ); Marin Vulic , U . S . PATENT DOCUMENTS Boston , MA (US ) 3 ,009 ,864 A 11/ 1961 Gordon - Aldterton et al. 3 ,228 ,838 A 1 / 1966 Rinfret (73 ) Assignee : Seres Therapeutics , Inc ., Cambridge , ( Continued ) MA (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 CN 102131928 A 7 /2011 EA 006847 B1 4 / 2006 U .S . C . 154 (b ) by 0 days. (Continued ) This patent is subject to a terminal dis claimer. OTHER PUBLICATIONS ( 21) Appl . No. : 14 / 765 , 810 Aas, J ., Gessert, C . E ., and Bakken , J. S . ( 2003) . Recurrent Clostridium difficile colitis : case series involving 18 patients treated ( 22 ) PCT Filed : Feb . 4 , 2014 with donor stool administered via a nasogastric tube .
    [Show full text]